CA2825716A1 - Use of (s) -esmolol for controlling venous irritation associated with the treatment of a cardiac disorder - Google Patents

Use of (s) -esmolol for controlling venous irritation associated with the treatment of a cardiac disorder Download PDF

Info

Publication number
CA2825716A1
CA2825716A1 CA2825716A CA2825716A CA2825716A1 CA 2825716 A1 CA2825716 A1 CA 2825716A1 CA 2825716 A CA2825716 A CA 2825716A CA 2825716 A CA2825716 A CA 2825716A CA 2825716 A1 CA2825716 A1 CA 2825716A1
Authority
CA
Canada
Prior art keywords
subject
phenylpropionate
isopropylamino
hydroxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2825716A
Other languages
English (en)
French (fr)
Inventor
Jerome H. Gass
Jeff Mckee
Barrett Rabinow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of CA2825716A1 publication Critical patent/CA2825716A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA2825716A 2011-01-27 2012-01-26 Use of (s) -esmolol for controlling venous irritation associated with the treatment of a cardiac disorder Abandoned CA2825716A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161436995P 2011-01-27 2011-01-27
US61/436,995 2011-01-27
PCT/US2012/022679 WO2012103305A1 (en) 2011-01-27 2012-01-26 Use of (s) - esmolol for controlling venous irritation associated with the treatment of a cardiac disorder

Publications (1)

Publication Number Publication Date
CA2825716A1 true CA2825716A1 (en) 2012-08-02

Family

ID=45567140

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2825716A Abandoned CA2825716A1 (en) 2011-01-27 2012-01-26 Use of (s) -esmolol for controlling venous irritation associated with the treatment of a cardiac disorder

Country Status (10)

Country Link
US (1) US8829047B2 (enExample)
EP (1) EP2667866B1 (enExample)
JP (1) JP2014511365A (enExample)
KR (1) KR20140019334A (enExample)
CN (1) CN103347513A (enExample)
AU (1) AU2012211309B2 (enExample)
BR (1) BR112013018598A2 (enExample)
CA (1) CA2825716A1 (enExample)
MX (1) MX2013008715A (enExample)
WO (1) WO2012103305A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8686036B2 (en) 2011-01-27 2014-04-01 Baxter International Inc. Methods of controlling heart rate while minimizing and/or controlling hypotension
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
JP2025509154A (ja) 2022-03-08 2025-04-11 エクアシールド メディカル リミテッド ロボット医薬品調製システムにおける流体移送ステーション

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU575153B2 (en) 1984-04-09 1988-07-21 Du Pont Merck Pharmaceutical Company, The Pharmaceutical compositions and method for treatment for prophylaxis of cardiac disorders
EP0248879A4 (en) 1985-12-04 1990-02-26 Du Pont PRODUCTION OF ARYLOXYPROPANOLAMINES AND ARYLÄTHANOLAMINES.
AU607437B2 (en) 1986-09-02 1991-03-07 Du Pont Pharmaceuticals Company Resolution of dl-methyl 3-(4-(2-hydroxy-3-isopropylamino) propoxy)phenylpropionate((dl-esmolol))
US4857552A (en) 1988-06-08 1989-08-15 E. I. Du Pont De Nemours And Co. Stable pharmaceutical composition
US5998019A (en) 1993-11-16 1999-12-07 Baxter International Inc. Multi-layered polymer structure for medical products
US5849843A (en) 1993-11-16 1998-12-15 Baxter International Inc. Polymeric compositions for medical packaging and devices
US5977409A (en) * 1997-04-15 1999-11-02 University Of Toledo Method of using α-substituted benzylamine chiral auxiliary synthetic reagents
TWI277414B (en) * 2001-01-12 2007-04-01 Baxter Int Esmolol formulation
US6310094B1 (en) * 2001-01-12 2001-10-30 Baxter International Inc. Ready-to-use esmolol solution
WO2005014042A1 (ja) 2003-08-08 2005-02-17 Ono Pharmaceutical Co., Ltd. 短時間型β遮断薬を有効成分とする心拍数減少剤
US20080293814A1 (en) 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
CN101323580A (zh) 2008-07-25 2008-12-17 河北科技大学 手性芳氧丙醇胺类化合物及其盐的合成方法
CN101881755B (zh) 2009-05-04 2013-05-29 南京海辰药业有限公司 通过高效液相色谱法检测盐酸艾司洛尔光学异构体的方法
CN101891636A (zh) 2009-05-21 2010-11-24 南京海辰药业有限公司 制备盐酸艾司洛尔光学异构体的新方法
CN102106846A (zh) 2009-12-23 2011-06-29 南京海辰药业有限公司 左旋盐酸艾司洛尔药物组合物及其制备方法
US8686036B2 (en) 2011-01-27 2014-04-01 Baxter International Inc. Methods of controlling heart rate while minimizing and/or controlling hypotension

Also Published As

Publication number Publication date
WO2012103305A1 (en) 2012-08-02
EP2667866A1 (en) 2013-12-04
EP2667866B1 (en) 2015-05-20
US8829047B2 (en) 2014-09-09
MX2013008715A (es) 2013-08-29
JP2014511365A (ja) 2014-05-15
AU2012211309B2 (en) 2014-10-09
CN103347513A (zh) 2013-10-09
BR112013018598A2 (pt) 2016-10-18
AU2012211309A1 (en) 2013-05-02
KR20140019334A (ko) 2014-02-14
US20120277309A1 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
AU2012211309B2 (en) Use of (S) - esmolol for controlling venous irritation associated with the treatment of a cardiac disorder
EP2911511B1 (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US10561607B2 (en) Pharmaceutical compositions comprising gels and methods for fabricating thereof
US20120220637A1 (en) Ophthalmologic Compositions And Use Mode Thereof
SK1682002A3 (en) Aqueous formulation containing moxifloxacin and sodium chloride, method of producing and use thereof
PT1368019E (pt) Formulação de esmolol
CA2410446C (en) Esmolol formulation
US9084763B2 (en) Methods for treating tachycardia and/or controlling heart rate while minimizing and/or controlling hypotension
US20200155450A1 (en) Pharmaceutical compositions comprising gels and methods for fabricating thereof
US10039728B1 (en) More potent and less toxic formulations of epinephrine and methods of medical use
AU2008256949B2 (en) Multi-dose concentrate esmolol with benzyl alcohol
CN120131545A (zh) 含美洛昔康的药物组合物溶液、及其制备方法和应用
HK1118211A (en) Ophthalmologic compositions and use mode thereof
HK1213434B (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180126